TISIDB

Summary
Symbol	MYO1B
Name	myosin IB
Aliases	myr1; MMI-alpha; MMIa; MYH-1c; MYO1B variant protein; myosin I alpha; myosin-I alpha; myosin-Ib; Unconventio ......
Chromosomal Location	2q12-q34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	-
Domain	PF00612 IQ calmodulin-binding motif PF00063 Myosin head (motor domain) PF06017 Unconventional myosin tail
Function	Motor protein that may participate in process critical to neuronal development and function such as cell migration, neurite outgrowth and vesicular transport.

> Gene Ontology [ TOP ]
Biological Process	GO:0006892 post-Golgi vesicle-mediated transport GO:0007015 actin filament organization GO:0030048 actin filament-based movement GO:0048193 Golgi vesicle transport GO:0051017 actin filament bundle assembly GO:0061572 actin filament bundle organization
Molecular Function	GO:0000146 microfilament motor activity GO:0003774 motor activity GO:0003779 actin binding GO:0005516 calmodulin binding GO:0005543 phospholipid binding GO:0005546 phosphatidylinositol-4,5-bisphosphate binding GO:0005547 phosphatidylinositol-3,4,5-trisphosphate binding GO:0016887 ATPase activity GO:0030898 actin-dependent ATPase activity GO:0035091 phosphatidylinositol binding GO:0042623 ATPase activity, coupled GO:0045296 cadherin binding GO:0050839 cell adhesion molecule binding GO:0051015 actin filament binding GO:0098631 protein binding involved in cell adhesion GO:0098632 protein binding involved in cell-cell adhesion GO:0098641 cadherin binding involved in cell-cell adhesion GO:1901981 phosphatidylinositol phosphate binding GO:1902936 phosphatidylinositol bisphosphate binding
Cellular Component	GO:0005769 early endosome GO:0005802 trans-Golgi network GO:0005884 actin filament GO:0005903 brush border GO:0005913 cell-cell adherens junction GO:0010008 endosome membrane GO:0015629 actin cytoskeleton GO:0016459 myosin complex GO:0030175 filopodium GO:0031984 organelle subcompartment GO:0032588 trans-Golgi network membrane GO:0044440 endosomal part GO:0098791 Golgi subcompartment GO:0098858 actin-based cell projection GO:0098862 cluster of actin-based cell projections

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	-

Summary
Symbol	MYO1B
Name	myosin IB
Aliases	myr1; MMI-alpha; MMIa; MYH-1c; MYO1B variant protein; myosin I alpha; myosin-I alpha; myosin-Ib; Unconventio ......
Chromosomal Location	2q12-q34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between MYO1B and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	MYO1B
Name	myosin IB
Aliases	myr1; MMI-alpha; MMIa; MYH-1c; MYO1B variant protein; myosin I alpha; myosin-I alpha; myosin-Ib; Unconventio ......
Chromosomal Location	2q12-q34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of MYO1B in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	Second most enriched score: 0.53	Sensitive to T cell-mediated killing
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	MYO1B
Name	myosin IB
Aliases	myr1; MMI-alpha; MMIa; MYH-1c; MYO1B variant protein; myosin I alpha; myosin-I alpha; myosin-Ib; Unconventio ......
Chromosomal Location	2q12-q34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of MYO1B in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.332	0.226
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.038	0.986
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.599	0.71
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.305	0.339
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-1.038	0.637
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.621	0.826
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.178	0.728
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.036	0.986
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.407	0.857
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.101	0.952
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.474	0.519
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.362	0.00202

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of MYO1B in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	5.9	-5.9	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	7.1	-7.1	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	1.4	2.3	0.469
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	1.7	2	0.532
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	0	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	9.1	7.7	1.4	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	16.7	0	16.7	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	8.3	-8.3	1

Summary
Symbol	MYO1B
Name	myosin IB
Aliases	myr1; MMI-alpha; MMIa; MYH-1c; MYO1B variant protein; myosin I alpha; myosin-I alpha; myosin-Ib; Unconventio ......
Chromosomal Location	2q12-q34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MYO1B. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	MYO1B
Name	myosin IB
Aliases	myr1; MMI-alpha; MMIa; MYH-1c; MYO1B variant protein; myosin I alpha; myosin-I alpha; myosin-Ib; Unconventio ......
Chromosomal Location	2q12-q34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MYO1B. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MYO1B. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	MYO1B
Name	myosin IB
Aliases	myr1; MMI-alpha; MMIa; MYH-1c; MYO1B variant protein; myosin I alpha; myosin-I alpha; myosin-Ib; Unconventio ......
Chromosomal Location	2q12-q34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MYO1B. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	MYO1B
Name	myosin IB
Aliases	myr1; MMI-alpha; MMIa; MYH-1c; MYO1B variant protein; myosin I alpha; myosin-I alpha; myosin-Ib; Unconventio ......
Chromosomal Location	2q12-q34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of MYO1B expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	MYO1B
Name	myosin IB
Aliases	myr1; MMI-alpha; MMIa; MYH-1c; MYO1B variant protein; myosin I alpha; myosin-I alpha; myosin-Ib; Unconventio ......
Chromosomal Location	2q12-q34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between MYO1B and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	MYO1B
Name	myosin IB
Aliases	myr1; MMI-alpha; MMIa; MYH-1c; MYO1B variant protein; myosin I alpha; myosin-I alpha; myosin-Ib; Unconventio ......
Chromosomal Location	2q12-q34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting MYO1B collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse MYO1B